Spexis announces positive renal impairment clinical trial results with balixafortide
Jotup,
The Phase 1 trial was designed to investigate the pharmacokinetics, safety and tolerability of BLX in subjects with mild (n=8)…
The Phase 1 trial was designed to investigate the pharmacokinetics, safety and tolerability of BLX in subjects with mild (n=8)…
News provided by Spexis AG Sep 22, 2022, 1:20 AM ET Phase 1 clinical trial in patients with renal impairment demonstrates…
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety…
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety…